Switch theme
Sign up to access all valuation multiples
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
1981
975
LTM Revenue $878M
LTM EBITDA $179M
$1.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Neogen has a last 12-month revenue (LTM) of $878M and a last 12-month EBITDA of $179M.
In the most recent fiscal year, Neogen achieved revenue of $895M and an EBITDA of -$936M.
Neogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Neogen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $878M | XXX | $895M | XXX | XXX | XXX |
| Gross Profit | $412M | XXX | $421M | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 47% | XXX | XXX | XXX |
| EBITDA | $179M | XXX | -$936M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | -105% | XXX | XXX | XXX |
| EBIT | -$832M | XXX | -$1.7M | XXX | XXX | XXX |
| EBIT Margin | -95% | XXX | 0% | XXX | XXX | XXX |
| Net Profit | -$866M | XXX | -$1.1B | XXX | XXX | XXX |
| Net Margin | -99% | XXX | -122% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $765M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Neogen's stock price is $5.
Neogen has current market cap of $1.2B, and EV of $1.9B.
See Neogen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.9B | $1.2B | XXX | XXX | XXX | XXX | $-3.99 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Neogen has market cap of $1.2B and EV of $1.9B.
Neogen's trades at 2.1x EV/Revenue multiple, and -4.1x EV/EBITDA.
Equity research analysts estimate Neogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neogen has a P/E ratio of -1.4x.
See valuation multiples for Neogen and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 10.8x | XXX | -4.1x | XXX | XXX | XXX |
| EV/EBIT | -2.3x | XXX | 82.9x | XXX | XXX | XXX |
| EV/Gross Profit | 4.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.4x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -33.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNeogen's last 12 month revenue growth is -7%
Neogen's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.4M for the same period.
Neogen's rule of 40 is -58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Neogen's rule of X is 4% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Neogen and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -7% | XXX | -5% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | -52% | XXX | XXX | XXX |
| EBITDA Growth | -8% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -58% | XXX | -58% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 4% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neogen acquired XXX companies to date.
Last acquisition by Neogen was XXXXXXXX, XXXXX XXXXX XXXXXX . Neogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Neogen founded? | Neogen was founded in 1981. |
| Where is Neogen headquartered? | Neogen is headquartered in United States of America. |
| How many employees does Neogen have? | As of today, Neogen has 975 employees. |
| Who is the CEO of Neogen? | Neogen's CEO is Mr. Mikhael Nassif. |
| Is Neogen publicy listed? | Yes, Neogen is a public company listed on NAS. |
| What is the stock symbol of Neogen? | Neogen trades under NEOG ticker. |
| When did Neogen go public? | Neogen went public in 1989. |
| Who are competitors of Neogen? | Similar companies to Neogen include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Neogen? | Neogen's current market cap is $1.2B |
| What is the current revenue of Neogen? | Neogen's last 12 months revenue is $878M. |
| What is the current revenue growth of Neogen? | Neogen revenue growth (NTM/LTM) is -7%. |
| What is the current EV/Revenue multiple of Neogen? | Current revenue multiple of Neogen is 2.2x. |
| Is Neogen profitable? | Yes, Neogen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Neogen? | Neogen's last 12 months EBITDA is $179M. |
| What is Neogen's EBITDA margin? | Neogen's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Neogen? | Current EBITDA multiple of Neogen is 10.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
